Citi raised the firm’s price target on Neurocrine (NBIX) to $203 from $175 and keeps a Buy rating on the shares following the Q3 beat. The firm says Crenessity significantly outperformed expectations in Q3 and is positioned to be a blockbuster.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth
- Neurocrine’s Strong Q3 Performance and Growth Potential Justify Buy Rating
- Neurocrine’s Strong Performance and Strategic Initiatives Drive Buy Rating
- Neurocrine reports Q3 adjusted EPS $2.17, consensus $2.07